{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:09Z","timestamp":1794072969071,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Dipartimenti di Eccellenza Program 2023-2027"],"award-info":[{"award-number":["Dipartimenti di Eccellenza Program 2023-2027"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101157011"],"award-info":[{"award-number":["101157011"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106881","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:53:00Z","timestamp":1785253980000},"page":"106881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Roctavian withdrawal: exploring the gap between innovation and healthcare system readiness in hemophilia A gene therapy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-3819","authenticated-orcid":false,"given":"Matteo Nicola Dario","family":"Di Minno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106881_bib1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jval.2021.05.008","article-title":"Hemophilia gene therapy value assessment: methodological challenges and recommendations","volume":"24","author":"Garrison","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.rpth.2026.106881_bib2","doi-asserted-by":"crossref","DOI":"10.4081\/btvb.2024.144","article-title":"The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art","volume":"3","author":"Di Minno","year":"2024","journal-title":"Bleed Thromb Vascul Biol"},{"key":"10.1016\/j.rpth.2026.106881_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106881_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101353","article-title":"Long-term durability of rAAV gene therapy in hemophilia: factor expression, clinical outcomes and underlying molecular mechanisms","volume":"75","author":"Dargaud","year":"2026","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2026.106881_bib5","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2026.106881_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/17474086.2026.2634281","article-title":"Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis","volume":"19","author":"Silva Mendes","year":"2026","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106881_bib7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.106881_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102640","article-title":"Gene therapy in hemophilia: the dawn of a new era","volume":"9","author":"Gualtierotti","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106881_bib9","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jtha.2025.02.042","article-title":"Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance","volume":"23","author":"Konkle","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106881_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jtha.2025.12.011","article-title":"Overview of gene therapy for hemophilia: questions and answers to navigate the innovation","volume":"24","author":"Hoffmann","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106881_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.zefq.2024.08.007","article-title":"[Marketing authorisation for rare diseases: the European regulatory perspective using the example of gene and cell therapies]","volume":"189","author":"Sch\u00fc\u00dfler-Lenz","year":"2024","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"10.1016\/j.rpth.2026.106881_bib12","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.jtha.2023.06.016","article-title":"Hemophilia gene therapy: first, do no harm","volume":"21","author":"Valentino","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106881_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric Validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.rpth.2026.106881_bib14","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.3324\/haematol.2023.284622","article-title":"Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies","volume":"109","author":"Di Minno","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106881_bib15","first-page":"1178","article-title":"A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B","volume":"30","author":"Alshehri","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.rpth.2026.106881_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40273-023-01335-x","article-title":"Using real-world data to inform value-based contracts for cell and gene therapies in Medicaid","volume":"42","author":"Zemplenyi","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.rpth.2026.106881_bib17","article-title":"Haemophilia: novel therapies and diagnostic challenges","author":"R\u00fchl","year":"2026","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.rpth.2026.106881_bib18","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1007\/s12325-025-03339-9","article-title":"Comparative effectiveness of valoctocogene roxaparvovec and efanesoctocog alfa in the treatment of severe hemophilia A: a matching-adjusted indirect comparison of bleeding frequency","volume":"42","author":"Douglas","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.106881_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2025028481","article-title":"Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy","volume":"147","author":"Kashiwakura","year":"2026","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:55:30Z","timestamp":1790164530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926035399"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106881","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roctavian withdrawal: exploring the gap between innovation and healthcare system readiness in hemophilia A gene therapy","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106881"}}